IPP Bureau
Remedium Lifecare secures Rs. 182.7 crore export deal
By IPP Bureau - May 16, 2025
The CDMO upgrade represents a transformational step for Remedium Lifecare
Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr
By IPP Bureau - May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
By IPP Bureau - May 16, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Sanofi India posts 27% growth in operating profits in Q1 2025
By IPP Bureau - May 16, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'
By IPP Bureau - May 14, 2025
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
By IPP Bureau - May 14, 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Bayer confirms 2025 targets after solid start to the year
By IPP Bureau - May 14, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
.jpg "Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr")
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
By IPP Bureau - May 14, 2025
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
By IPP Bureau - May 14, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Briefs: Zydus and CuraTeQ Biologics
By IPP Bureau - May 14, 2025
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
By IPP Bureau - May 14, 2025
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
By IPP Bureau - May 14, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa
By IPP Bureau - May 13, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Borealis advancing sustainability medical devices with the Bornewables
By IPP Bureau - May 13, 2025
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025
